News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
XOMA (US) LLC (XOMA) Will Present XOMA 358 Phase 1 Data At ENDO 2015 3/6/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec 3/5/2015
Asterias Biotherapeutics Initiates Patient Enrollment For Phase 1/2a Clinical Trial Of AST-OPC1 In Newly Injured People With Complete Cervical Spinal Cord Injury 3/5/2015
Ironwood Pharmaceuticals (IRWD) Initiates Phase I Clinical Study Of sGC Stimulator IW-1973 3/5/2015
Molecular Templates Inc. Announces Start Of Phase 1 Clinical Trial Of MT-3724 In Refractory Non-Hodgkin’s Lymphoma 3/5/2015
Eisai Company, Ltd. (ESALY.PK) And Merck & Co. (MRK) Enter Collaboration To Explore Novel Combination Regimens Of Anti-PD-1 Therapy With Multi-Targeting RTK Inhibitor And Microtubule Dynamics Inhibitor In Multiple Types Of Cancer 3/5/2015
Symbiomix Therapeutics, LLC Studies Show Drug Candidate For Women's Health Infections Is Safe And Well-Tolerated 3/4/2015
Immunomic Therapeutics Explains Proprietary LAMP-vax Platform In Nature Advertorial Supplement 3/4/2015
Aerpio Announces Publication Of Positive Results Of Phase 1b/2a Clinical Trial Of Novel Tie2 Activator, AKB-9778, For The Treatment Of Patients With Diabetic Macular Edema (DME) – TIME-1 Study 3/4/2015
Clinical Study Published In Neurology Finds That electroCore’s Non-Invasive Vagus Nerve Stimulation Is Effective In Treating Cluster Headaches 3/3/2015
Rutgers Cancer Institute Of New Jersey Starts ONC201 Clinical Trials 3/3/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer 3/3/2015
Adamis Pharmaceuticals (ADMP) Announces Positive Pharmacokinetic Study Results For Its Dry Powder Inhaler Product 3/3/2015
Pulmokine Receives $1 Million Investment From Broadview Ventures To Advance PAH Candidate Into First Clinical Trial 3/3/2015
Islet Sciences Enters Into Exclusive License Agreement For Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate 3/3/2015
DURECT Corporation (DRRX) Announces Epigenomic Regulator Program Including A New NAFLD/NASH And Acute Organ Injury Product Candidate In Development 3/3/2015
MyoKardia Announces Initiation Of Phase 1 Clinical Study Of MYK-461 For Hypertrophic Cardiomyopathy 3/3/2015
Cerulean Pharma Inc. (CERU) Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer 3/3/2015
Epizyme (EPZM) Announces Presentation Of Data From Phase 1 Study Of EZH2 Inhibitor EPZ-6438 (E7438) 3/3/2015
Boehringer Ingelheim Puts Hold on Key Alzheimer's Drug Trial 3/2/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Cancer Of The Fallopian Tube 3/2/2015
TRACON Pharmaceuticals, Inc. (TCON) Announces Positive Phase 1b Results For TRC105 In Combination With Inlyta (Axitinib) At The ASCO 2015 Genitourinary Cancers Symposium 3/2/2015
Almac Discovery Initiates Phase 1 Study Of ALM201 For The Treatment Of Patients With Advanced Ovarian Cancer And Other Solid Tumours 3/2/2015
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc. (VTAE) Release: BACE Inhibitor BI 1181181 Voluntarily Put On Temporary Clinical Hold For Safety Evaluation 2/27/2015
INSYS Therapeutics Announces Its Pharmaceutical Cannabidiol Received Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 2/27/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
Sangamo BioSciences (SGMO) Presents New Clinical Data At CROI 2015 From Trial Of ZFP Therapeutic Designed To Provide Functional Control Of HIV 2/26/2015
ObsEva Reports Positive Phase 1 Results For The First Orally Active Oxytocin Antagonist OBE001 To Treat Preterm Labour 2/26/2015
Innocrin Pharmaceuticals Inc. To Present Interim Results From Its Phase 1/2 Prostate Cancer Clinical Study And Preclinical Results That Demonstrate VT-464 Efficacy In A Clinically-Relevant Enzalutamide-Resistant Mouse Model 2/26/2015
Ampio Pharmaceuticals, Inc. (AMPE) Announces Top-Line Results Of The Double-Blind Multiple Intra-Articular Injections (STRUT) Study Of Ampion In Patients With Moderate To Severe Osteoarthritis Of The Knee 2/25/2015
Anavex (AVXL) Release: ANAVEX 2-73 Could Prevent Alzheimer's Disease In Addition To Modifying And Treating Symptoms 2/25/2015
Cell MedX Corp. (CMXC) Announces Results Of Preliminary Analysis Of Metabolomic Assays In Phase 1 Pilot Clinical Trial 2/25/2015
Adamis Pharmaceuticals (ADMP) Announces Positive Pharmacokinetic Study Results For Its Beclomethasone Dipropionate HFA Product 2/24/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions In Prekallikrein Levels 2/24/2015
Bavarian Nordic (BAVA.CO) Announces Updated Overall Survival Data From Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The 2015 Genitourinary Cancers Symposium 2/24/2015
BioTime (BTX) Announces First Patient Treated In Pivotal Clinical Trial Of Renevia™ For HIV-Associated Lipoatrophy 2/24/2015
Enanta Pharmaceuticals, Inc. Announces JAMA Publication Of Results From AbbVie (ABBV)’s Study Of VIEKIRA PAK™ (Ombitasvir, Paritaprevir, Ritonavir Tablets; Dasabuvir Tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) 2/23/2015
Arrowhead Research Corporation (ARWR) Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency 2/23/2015
ReveraGen BioPharma Announces Start Of Phase 1 Clinical Trial Of VBP15 Dissociative Steroid Drug 2/18/2015
Dipexium Pharmaceuticals (DPRX) Announces Successful Completion And Initial Results Of Phase 1 Skin Sensitization Trial Of Locilex 2/17/2015
Helix Biopharma (TSX:HBP) Initiates Enrollment for Eleventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 2/17/2015
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Treatment Shows Efficacy And Tolerability In Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant 2/17/2015
Stealth Biotherapeutics Initiates A Clinical Study Of Bendavia For The Treatment Of Orphan Mitochondrial Diseases 2/17/2015
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Colorectal Cancer 2/17/2015
Anaheim Clinical Trials (ACT) ‘Slam Dunks’ Enrollment On Another Japanese Bridging Study 2/16/2015
Galapagos NV (GLPG.BR) Reports Positive Phase 1 Results For GLPG1690 2/16/2015
Bexion Pharmaceuticals Receives Orphan Drug Designation For Saposin C, The Active Ingredient In BXQ-350 For Glioblastoma Multiforme From FDA 2/16/2015
Soligenix (SNGX) Release: Ricin Toxin Vaccine Poster Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC 2/13/2015
Genzyme (GENZ) Presents Data From Its Phase 1b Program For Niemann-Pick Type B At The Lysosomal Disease Network’s WORLD Symposium 2015 2/13/2015
Verastem, Inc. (VSTM) Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma 2/12/2015
Novavax, Inc. (NVAX) Announces Initiation Of Ebola Vaccine Phase 1 Clinical Trial Supported By Non-Human Primate Challenge Data And Documented Rapid Manufacturing Capabilities 2/12/2015
Oncobiologics Inc. Announces ONS-3010 (Humira/Adalimumab Biosimilar) Meets Primary Endpoints In First Clinical Study 2/12/2015
Aileron Therapeutics Initiates Phase 1 Cancer Study Of ALRN-6924 In Advanced Hematologic And Solid Malignancies With Wild Type P53 2/12/2015
BIOCEO15: BioLineRx Ltd. CEO Touts New Celiac Drug, Fleshes Out Novartis AG (NVS) Partnership Terms 2/11/2015
ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Meets Primary Endpoint In First Human Clinical Study 2/11/2015
Immune Design Corporation (IMDZ) Announces First Patients Dosed In Phase 1 Clinical Trial Of G100 Investigational Immuno-Oncology Agent 2/11/2015
Ultragenyx Pharmaceuticals (RARE) Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7 2/11/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Ovarian Cancer 2/11/2015
Edge Therapeutics Reports Initial Data From Its Phase 1/2 NEWTON Trial For EG-1962 For Improvement Of Outcomes After Ruptured Brain Aneurysm 2/11/2015
Heron Therapeutics, Inc. (APPA) Initiates Phase 1 Clinical Study Of HTX-011 For The Treatment Of Post-Operative Pain 2/11/2015
Theravance Biopharma Initiates Patient Registry Study For VIBATIV(R) (telavancin) 2/11/2015
BIOCEO15: ContraFect (CFRXU) CEO Says Lysin, AB Anti-Infectives Are “Game-Changers” in 2015 2/10/2015
Synthetic Biologics, Inc. (SYN) Announces Positive Topline Results From Phase 1b Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile Infection 2/10/2015
Apellis Pharmaceuticals Enters Clinical Testing Phase In Its Age-Related Macular Degeneration Program 2/10/2015
Strategic Science & Technologies Initiates Phase 1 Study To Evaluate Topical Sildenafil In Women With Female Sexual Arousal Disorder 2/9/2015
Alkermes plc (ALKS) Announces Positive Topline Results From Phase 1 Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 2/9/2015
Trevena, Inc. (TRVN) Announces Positive Results From Phase 1 Multiple Ascending Dose Study Of TRV734 For Moderate To Severe Acute And Chronic Pain 2/9/2015
Safety And Preliminary Efficacy Of Human Neural Stem Cells In StemCells (STEM)'s Dry AMD Study To Be Presented At Ophthalmology Conference 2/5/2015
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Non-Small Cell Lung Cancer 2/5/2015
THERAVECTYS Obtains Orphan Drug Designation From European Medicines Agency For Its Lentiviral Vector-Based Therapeutic Vaccine Against Adult T-Cell Leukemia And Lymphoma 2/5/2015
Proteostasis Therapeutics, Inc. Announces A New Class Of Agents For Cystic Fibrosis Called CFTR Amplifiers And Selects PTI130 As A Development Candidate 2/5/2015
Akaal Pharma Announces Positive Results From Phase 1 Clinical Study Of Novel Topical AKP-11 For The Treatment Of Psoriasis 2/5/2015
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus FOLFOX In Advanced Gastrointestinal Malignancies 2/3/2015
bluebird bio (BLUE)'s Rare Blood Disorder Drug Tagged a Breakthrough by the FDA 2/3/2015
bluebird bio (BLUE) Release: FDA Grants Breakthrough Therapy Designation To Lentiglobin For Treatment Of Beta-Thalassemia Major 2/2/2015
Pluristem Therapeutics (PSTI) Announces Significant New Finding From Its Phase I/II Muscle Injury Trial And Excellent Safety Profile For PLX-PAD Cells At Twelve Months 2/2/2015
Protalix Biotherapeutics, Inc. (PLX) Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease 2/2/2015
Bionomics Limited (BNO.AX) Begins Phase 1b Study With Anxiety Drug Bnc210 2/2/2015
Kamada Ltd. (KMDA) Reports Encouraging Interim Data From Its Phase 1/2 Extension Study: AAT In Pediatric Patients With Type 1 Diabetes 2/2/2015
Alnylam Pharmaceuticals (ALNY) Initiates Phase 1/2 Clinical Trial For ALN-CC5, A Subcutaneously Administered Rnai Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases 2/2/2015
Rock Creek Pharmaceuticals Receives Clinical Trial Application Approval 1/30/2015
First Trial Finds GlaxoSmithKline (GSK) Ebola Shot Safe 1/29/2015
XencorReports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction Of Serum Ige In Healthy Volunteers 1/29/2015
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity In Rheumatoid Arthritis 1/29/2015
Celldex Therapeutics, Inc. (CLDX) And Bristol-Myers Squibb Company (BMY) Announce Initiation Of Phase 1/2 Combination Study Of Varlilumab And Opdivo® In Advanced Refractory Solid Tumors 1/29/2015
Cleveland Biolabs Inc. (CBLI) Announces Oncology Clinical Development Update For Entolimod 1/29/2015
International Stem Cell Corporation To Conduct Parkinson's Disease Clinical Study In Australia 1/29/2015
Endexx Announces Positive Results Of Initial Diabetic Neuropathy Patient Study 1/29/2015
aTyr Pharma Inc. Announces First FSHD Patient Study Of Resolaris™ 1/28/2015
RestorGenex Granted Orphan Drug Designation For RES-529 For Treatment Of Glioblastoma Multiforme 1/28/2015
Sorrento Therapeutics, Inc. Announces Completion Of Enrollment In The Cynviloq™ Registrational TRIBECA™ Study 1/28/2015
Synageva BioPharma (GEVA) Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted 1/26/2015
Pharmacyte Biotech's Expanded Follow-Up Study On Malignant Ascites Fluid Accumulation In Final Stages Of Preparation 1/26/2015
Cellceutix (CTIX) Plans Clinical Trial In Patients With Ulcerative Proctitis 1/26/2015
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 1/23/2015
Minerva Neurosciences, Inc. (NERV) Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist For Treatment Of Sleep Disorders Including Primary And Comorbid Insomnia 1/22/2015
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence First-In-Human Clinical Trials Of ADXS-HER2 1/22/2015
Disneyland Measles Outbreak Casts Shadow on Anti-Vaccination Movement 1/21/2015
Tekmira (TKMR) Initiates Phase I Clinical Trial Of TKM-HBV 1/21/2015
Adocia Initiates A Clinical Study On The Post-Meal Effect Of Ultra-Rapid Biochaperone Lispro Insulin Formulation 1/21/2015
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-391 Ointment For Actinic Keratosis In A Phase 1 Clinical Study 1/20/2015
Tobira Therapeutics Inc. Doses First Subject In Phase 1 Clinical Trial Of Cenicriviroc And Pioglitazone 1/20/2015
Spark Therapeutics Initiates Phase 1/2 Clinical Trial Of SPK-CHM For Choroideremia, Expanding Its Pipeline Of Potential Treatments For Rare, Blinding Conditions 1/20/2015
Immunomedics, Inc. (IMMU) Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) In Patients With Metastatic Gastrointestinal Cancers 1/20/2015
Kite Pharma, Inc. (KITE) Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process 1/20/2015
Verastem, Inc. (VSTM) Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma 1/20/2015
Cellceutix (CTIX) Reports Spleen Lesion "Disappears" In Patient With Metastatic Stage 4 Ovarian Cancer In Clinical Trial Of Anti-Cancer Drug Kevetrin 1/20/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Final Phase 1b Safety, Efficacy And Biomarker Data For Tarextumab In Pancreatic Cancer At The 2015 Gastrointestinal Cancer Symposium 1/19/2015
Neurocrine Biosciences, Inc. (NBIX) Announces Granting Of Orphan Drug Status For NBI-77860 In Congenital Adrenal Hyperplasia 1/19/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
J.P. Morgan: Five Prime Therapeutics, Inc. (FPRX) CEO Says Experimental Drug to Head Into Six New Tumor Trials Via Bristol-Myers Squibb Company (BMY) 1/16/2015
J.P. Morgan: Juno Therapeutics (JUNO) Touts 10 New Drugs for Six Diseases, Loves New CAR-T Platform 1/16/2015
Antibe Therapeutics Inc. (ATE.V) Suspends Its Phase I Clinical Trial Due To Safety Concerns 1/16/2015
Pfizer (PFE)'s Working on Once-a-Year Anti-Cholesterol Shot 1/15/2015
Auspex Pharmaceuticals (ASPX) Receives FDA Orphan Drug Designation Of SD-809 For Treatment Of Tourette Syndrome In The Pediatric Population 1/15/2015
OncoMed Pharmaceuticals, Inc. (OMED) Enrolls First Biomarker-Selected Patient In Expansion Stage Of Anti-Notch1 Phase 1a Trial In Solid Tumors 1/15/2015
Novan Therapeutics To Present Successful Clinical Study Results Of Lead Product Candidate SB204 For The Treatment Of Acne Vulgaris 1/15/2015
Newron Pharmaceuticals (NWRN) Announces Results Of Phase I Study Of NW-3509 Phase II Study In Schizophrenia Patients Planned For Q2 2015 1/15/2015
Aptose Biosciences Doses First Patient In Phase 1b Clinical Study Of APTO-253 In Relapsed Or Refractory Hematological Malignancies 1/14/2015
Ascendis Pharma A/S Announces Initiation Of A Phase 1 Single Ascending Dose Study Of Transcon Treprostinil 1/14/2015
Sarepta (SRPT) Announces First Patient Dosed In European Phase1/2 Study Of SRP-4053 In Duchenne Muscular Dystrophy Patients 1/14/2015
BioLine Announces Completion Of Enrollment In CE Mark Registration Trial Of BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction 1/14/2015
BioMarin (BMRN) Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study Of BMN 190 For Treatment Of CLN2 Disorder, A Form Of Batten Disease 1/13/2015
Relmada Therapeutics Reaches Midway Point In Dose Escalation For Phase One Study Of Novel NMDA Receptor Antagonist D-Methadone 1/13/2015
PsiOxus Therapeutics Limited Release: European Medicines Agency Grants Positive Opinion For Orphan Drug Status For Ovarian Cancer Oncolytic Vaccine 1/13/2015
Bellicum Pharmaceuticals, Inc. Announces Successful Dosing Of First Patient Cohort With BPX-501 T Cells Following Haplo-Identical Hematopoietic Stem Cell Transplant 1/13/2015
Auspex Pharmaceuticals (ASPX) Announces Favorable Topline Results From Thorough QT Clinical Trial Of SD-809 1/12/2015
Lipocine Inc. (LPCN) Announces Positive Phase 1b Top-Line Results With LPCN 1107 In Pregnant Women 1/12/2015
Second Genome Advances Lead Microbiome Drug Development Program In Phase I Clinical Trial As A Treatment For Inflammatory Bowel Disease 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
TapImmune Inc. (TPIV) Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials 1/12/2015
Cornerstone Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of CPI-613 For The Treatment Of Metastatic Colorectal Cancer 1/12/2015
Sorrento Therapeutics, Inc. Provides Status Update On The Cynviloq™ Registrational TRIBECA™ Study 1/12/2015
ProteoTech Is Granted Orphan Drug Designation For Systebryl™ (PTI-110) For The Treatment Of AL Amyloidosis 1/12/2015
Scancell To Provide Positive SCIB1 Phase 1/2 Clinical Trial Update During Corporate Presentations 12-15 January, San Francisco 1/12/2015
FDA Approves Cytori Therapeutics, Inc. (CYTX) U.S. Pivotal Scleroderma Trial 1/12/2015
Alnylam Pharmaceuticals (ALNY) Reports Initial Evidence For Potential Correction Of The Hemophilia Phenotype In Phase 1 Study Of ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia 1/12/2015
ReVance Therapeutics, Inc. (RVNC) Announces Publication of Positive Results From RT002 Phase 1/2 Study 1/9/2015
Journal Of Cardiovascular Pharmacology Publishes Positive Nonclinical Results Of Proteon Therapeutics, Inc. (PRTO)'s PRT-201 In Peripheral Artery Disease 1/9/2015
SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial And Emergency Use Program Of SAGE-547 In Patients With Super-Refractory Status Epilepticus 1/9/2015
TONIX Pharmaceuticals, Inc. (TNXP) Announces Clinical Progress On Potential Treatment for Headache 1/9/2015
Regen BioPharma Identifies Second Generation Gene Silencing Candidates For Blocking Cancer Stem Cell Gene Target 1/9/2015
CoMentis, Inc. And Anvyl Announce The Initiation Of Clinical Trials For APN1125 For The Treatment Of Schizophrenia 1/9/2015
BEAT BioTherapeutics dATP Technology Improves Cardiac Function In End Stage Human Heart Failure Cardiac Muscle 1/9/2015
TRACON Pharmaceuticals, Inc. Announces Results From A Clinical Trial Of TRC105 In Patients With Hepatocellular Carcinoma To Be Presented At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/9/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Interim Data From Phase 1/2 Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease 1/8/2015
Karyopharm Therapeutics (KPTI) Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma 1/8/2015
First Patient Successfully Transplanted With Cryopreserved (Frozen) Nicord® In Gamida Cell Ltd.'s Ongoing Phase I/II Clinical Trial For Blood Cancers 1/8/2015
Cleave Biosciences Initiates Phase 1 Clinical Trial Of CB-5083 In Patients With Advanced Solid Tumors 1/8/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Isarna Therapeutics Unveils New Selective TGF-Beta Antagonist Program Targeting Multiple Indications In Ophthalmology 1/8/2015
Targovax Reports Completion Of Recruitment Of Patients In The Phase 1/2 Clinical Trial CT TG01-01 1/8/2015
Principia Biopharma Successfully Completes Phase 1 Clinical Trial Of PRN1008, A Novel Oral BTK Inhibitor For Autoimmune Diseases 1/8/2015
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 Is Safe With Potential For Therapeutic Effect On Fibrosis In NASH Patients With Advanced Fibrosis 1/7/2015
Arena Pharmaceuticals, Inc. (ARNA) Reports Positive Results From Phase 1b Clinical Trial Evaluating APD334 For The Treatment Of Autoimmune Diseases 1/7/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
Cortice Biosciences Announces Enrollment Of A Phase 1 Trial Evaluating TPI 287 Plus Radiotherapy For Treatment Of Lung And Breast Cancer Metastases To The Brain 1/7/2015
Johnson & Johnson (JNJ) Starts Ebola Vaccine Testing in Humans 1/6/2015
Johnson & Johnson (JNJ) Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen 1/6/2015
GliaCure Completes Phase 1a Clinical Trial In Alzheimer's Disease 1/6/2015
Celsion Corporation (CLSN) Submits DNA-Based Immunotherapy Clinical Protocol To The FDA As Part Of A First Line Treatment For Ovarian Cancer 1/6/2015
Inovio Pharmaceuticals (INO) HIV Immunotherapy Shows Characteristics Considered Vital To Treating HIV 1/6/2015
cCAM Biotherapeutics Receives FDA Approval To Initiate Phase 1 Trial For CM-24, A Novel Immune Checkpoint Inhibitor For Cancer Immunotherapy 1/6/2015
Bavarian Nordic (BAVA.CO) Announces Initiation Of Phase 1 Clinical Trial For The Ebola Vaccine Regimen Of MVA-BN® Filo And Janssen's AdVac® technology 1/6/2015
BioLineRx Ltd. Completes Dose Escalation Stage Of Phase 1 Trial For Novel Stem Cell Mobilization Treatment 1/6/2015
Cleveland Biolabs Inc. (CBLI) And Incuron Announce Updates On Clinical Progress With Curaxin CBL0137 1/6/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
Anavex Life Sciences Corp. (AVXL) Encouraged by Scientific Data Confirming Sigma-1 Receptor's Beneficial Direct Interaction With Cannabinoid Receptor 1/6/2015
OncoMed Pharmaceuticals, Inc. (OMED) Doses First Patient In Phase 1 Clinical Trial Of Novel Anti-DLL4/VEGF Bispecific Antibody 1/5/2015
Alnylam Pharmaceuticals (ALNY) Files Clinical Trial Application To Initiate A Phase 1 Study For ALN-AS1, A Subcutaneously Administered, Investigational Rnai Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) For The Treatment Of Hepatic Porphyrias 1/5/2015
Merck & Co. (MRK), NewLink Genetics Ebola Vaccine Trial Resumes in Geneva 1/5/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
Tekmira (TKMR) Provides Update On TKM-PLK1 Phase I/II Clinical Study In Patients With Advanced Gastrointestinal Neuroendocrine Tumors And Adrenocortical Carcinoma 12/31/2014
Idera Pharmaceuticals, Inc. (IDRA) Provides Key Updates On Clinical Development Of IMO-8400 For Treatment Of Waldenstrom's Macroglobulinemia 12/30/2014
Synthetic Biologics, Inc. (SYN) Announces First Patient Dosed In Phase 1b Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/30/2014
Soligenix (SNGX) Announces Publication of Combination Ricin/Anthrax Vaccine Data 12/29/2014
AEterna Zentaris (AEZS): Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin In Prostate Cancer Published In Clinical Cancer Research 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-361 In A Phase 1 Clinical Study 12/24/2014
Novastem Treats First Patient Using Stemedica Cell Technologies, Inc.'s Mesenchymal And Neural Stem Cell Combination Therapy For Ischemic Stroke 12/24/2014
Mirati Therapeutics  (MRTX) Doses First Patient In Expansion Cohorts Of Phase 1b Trial Of MGCD265 In Genetically Selected Patients 12/23/2014
Helix Biopharma (TSX:HBP) Announces Initiation Of First Clinical Site For US Study 12/23/2014
Tekmira (TKMR) Receives Clearance To Conduct A Phase I Clinical Study With TKM-HBV 12/22/2014
New Published Data Show Pluristem Therapeutics (PSTI)'s PLX Cells Protect Neurons 12/22/2014
Synthetic Biologics, Inc. (SYN) Announces Positive Topline Results From Phase 1a Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/22/2014
Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use Of Dermal Sheath Cup Cells To Treat Pattern Baldness 12/22/2014
Relmada Therapeutics Doses First Cohort Of Subjects In Human Clinical Trial Of D-Methadone 12/22/2014
AGA's GERD Registry Enrolls First Patients 12/22/2014
ContraFect Corporation (CFRXU) Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections 12/22/2014
Galapagos NV (GLPG.BR) Initiates First Phase 1 Study In Cystic Fibrosis And Will Receive Milestone Payment From AbbVie (ABBV) 12/19/2014
Curis, Inc. (CRIS) Announces Dosing Of First Patient In Phase 1 Trial Of CUDC-907 In Patients With Advanced/ Relapsed Solid Tumors 12/18/2014
Inovio Pharmaceuticals (INO) Initiates DNA Immunotherapy Trial For Breast, Lung And Pancreatic Cancers 12/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014
Seattle Genetics, Inc. (SGEN) Initiates Phase 1b Trial Of SGN-CD33A In Combination With Frontline Standard Of Care And As Consolidation Therapy For Acute Myeloid Leukemia 12/18/2014
Dyax Corp. (DYAX)'s First-In-Human Trial For DX-2930 Conducted By Vince And Associates Clinical Research Featured In The Annals Of Allergy, Asthma & Immunology 12/18/2014
e-Therapeutics plc Reports Progress In ETS2101 Phase 1a And Oral Dosing Studies 12/18/2014
Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data From Phase 1b Trial Of I.V. CR845 In Dialysis Patients 12/17/2014



//-->